Cargando…

Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis

OBJECTIVE: To investigate β‐amyloid and tau depositions using Pittsburgh compound B (PiB) positron emission tomography (PET) and AV1451 tau PET imaging in aging multiple sclerosis (MS) patients. METHODS: Patients with MS (n = 16) and controls (n = 80) matched for age, sex, and APOE ε4 status from th...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeydan, Burcu, Lowe, Val J., Reichard, Ross R., Przybelski, Scott A., Lesnick, Timothy G., Schwarz, Christopher G., Senjem, Matthew L., Gunter, Jeffrey L., Parisi, Joseph E., Machulda, Mary M., Vemuri, Prashanthi, Mielke, Michelle M., Knopman, David S., Petersen, Ronald C., Jack, Clifford R., Kantarci, Orhun H., Kantarci, Kejal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7078013/
https://www.ncbi.nlm.nih.gov/pubmed/31970802
http://dx.doi.org/10.1002/ana.25684
_version_ 1783507537794957312
author Zeydan, Burcu
Lowe, Val J.
Reichard, Ross R.
Przybelski, Scott A.
Lesnick, Timothy G.
Schwarz, Christopher G.
Senjem, Matthew L.
Gunter, Jeffrey L.
Parisi, Joseph E.
Machulda, Mary M.
Vemuri, Prashanthi
Mielke, Michelle M.
Knopman, David S.
Petersen, Ronald C.
Jack, Clifford R.
Kantarci, Orhun H.
Kantarci, Kejal
author_facet Zeydan, Burcu
Lowe, Val J.
Reichard, Ross R.
Przybelski, Scott A.
Lesnick, Timothy G.
Schwarz, Christopher G.
Senjem, Matthew L.
Gunter, Jeffrey L.
Parisi, Joseph E.
Machulda, Mary M.
Vemuri, Prashanthi
Mielke, Michelle M.
Knopman, David S.
Petersen, Ronald C.
Jack, Clifford R.
Kantarci, Orhun H.
Kantarci, Kejal
author_sort Zeydan, Burcu
collection PubMed
description OBJECTIVE: To investigate β‐amyloid and tau depositions using Pittsburgh compound B (PiB) positron emission tomography (PET) and AV1451 tau PET imaging in aging multiple sclerosis (MS) patients. METHODS: Patients with MS (n = 16) and controls (n = 80) matched for age, sex, and APOE ε4 status from the population‐based Mayo Clinic Study of Aging who underwent PiB PET imaging were studied. Of these individuals, 12 patients with MS and 60 matching controls also underwent AV1451 tau PET. Cortical PiB and AV1451 standard uptake value ratios (SUVrs) from the entire cortex and previously determined Alzheimer disease (AD) signature regions in the same population were calculated for group comparisons and testing for associations with age. RESULTS: AD signature PiB SUVr (odds ratio [OR] [95% confidence interval (CI)] = 0.52 [0.27–0.98], p = 0.044), total cortical PiB SUVr (OR [95% CI] = 0.52 [0.28–0.99], p = 0.048), and the frequency of abnormal PiB SUVrs (OR [95% CI] = 0.10 [0.01–0.90], p = 0.040) were lower in MS than controls. Although AD‐signature and total cortical AV1451 SUVrs were not different between the groups, the frequency of abnormal AV1451 SUVrs was higher (OR [95% CI] = 10.65 [1.10–103.35], p = 0.041) in MS than controls. The association of AD signature PiB SUVr with age was steeper in the controls compared to patients with MS (estimate [95% CI] = −0.14 [−0.023 to −0.006], p = 0.002). Similarly, the association of total cortical PiB SUVr with age was steeper in the controls compared to patients with MS (estimate [95% CI] = −0.13 [−0.021 to −0.005], p = 0.002). There was no difference in the association of AV1451 SUVr findings with age between the MS patients and controls. INTERPRETATION: Although both β‐amyloid and tau are biomarkers of cognitive aging and AD, cortical β‐amyloid deposition was lower in MS than age‐matched controls, suggesting that some aspect of MS pathobiology retards the accumulation of β‐amyloid but not the accumulation of tau. ANN NEUROL 2020;87:556–567
format Online
Article
Text
id pubmed-7078013
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-70780132020-04-15 Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis Zeydan, Burcu Lowe, Val J. Reichard, Ross R. Przybelski, Scott A. Lesnick, Timothy G. Schwarz, Christopher G. Senjem, Matthew L. Gunter, Jeffrey L. Parisi, Joseph E. Machulda, Mary M. Vemuri, Prashanthi Mielke, Michelle M. Knopman, David S. Petersen, Ronald C. Jack, Clifford R. Kantarci, Orhun H. Kantarci, Kejal Ann Neurol Research Articles OBJECTIVE: To investigate β‐amyloid and tau depositions using Pittsburgh compound B (PiB) positron emission tomography (PET) and AV1451 tau PET imaging in aging multiple sclerosis (MS) patients. METHODS: Patients with MS (n = 16) and controls (n = 80) matched for age, sex, and APOE ε4 status from the population‐based Mayo Clinic Study of Aging who underwent PiB PET imaging were studied. Of these individuals, 12 patients with MS and 60 matching controls also underwent AV1451 tau PET. Cortical PiB and AV1451 standard uptake value ratios (SUVrs) from the entire cortex and previously determined Alzheimer disease (AD) signature regions in the same population were calculated for group comparisons and testing for associations with age. RESULTS: AD signature PiB SUVr (odds ratio [OR] [95% confidence interval (CI)] = 0.52 [0.27–0.98], p = 0.044), total cortical PiB SUVr (OR [95% CI] = 0.52 [0.28–0.99], p = 0.048), and the frequency of abnormal PiB SUVrs (OR [95% CI] = 0.10 [0.01–0.90], p = 0.040) were lower in MS than controls. Although AD‐signature and total cortical AV1451 SUVrs were not different between the groups, the frequency of abnormal AV1451 SUVrs was higher (OR [95% CI] = 10.65 [1.10–103.35], p = 0.041) in MS than controls. The association of AD signature PiB SUVr with age was steeper in the controls compared to patients with MS (estimate [95% CI] = −0.14 [−0.023 to −0.006], p = 0.002). Similarly, the association of total cortical PiB SUVr with age was steeper in the controls compared to patients with MS (estimate [95% CI] = −0.13 [−0.021 to −0.005], p = 0.002). There was no difference in the association of AV1451 SUVr findings with age between the MS patients and controls. INTERPRETATION: Although both β‐amyloid and tau are biomarkers of cognitive aging and AD, cortical β‐amyloid deposition was lower in MS than age‐matched controls, suggesting that some aspect of MS pathobiology retards the accumulation of β‐amyloid but not the accumulation of tau. ANN NEUROL 2020;87:556–567 John Wiley & Sons, Inc. 2020-02-08 2020-04 /pmc/articles/PMC7078013/ /pubmed/31970802 http://dx.doi.org/10.1002/ana.25684 Text en © 2020 The Authors. Annals of Neurology published by Wiley Periodicals, Inc. on behalf of American Neurological Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Research Articles
Zeydan, Burcu
Lowe, Val J.
Reichard, Ross R.
Przybelski, Scott A.
Lesnick, Timothy G.
Schwarz, Christopher G.
Senjem, Matthew L.
Gunter, Jeffrey L.
Parisi, Joseph E.
Machulda, Mary M.
Vemuri, Prashanthi
Mielke, Michelle M.
Knopman, David S.
Petersen, Ronald C.
Jack, Clifford R.
Kantarci, Orhun H.
Kantarci, Kejal
Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis
title Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis
title_full Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis
title_fullStr Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis
title_full_unstemmed Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis
title_short Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis
title_sort imaging biomarkers of alzheimer disease in multiple sclerosis
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7078013/
https://www.ncbi.nlm.nih.gov/pubmed/31970802
http://dx.doi.org/10.1002/ana.25684
work_keys_str_mv AT zeydanburcu imagingbiomarkersofalzheimerdiseaseinmultiplesclerosis
AT lowevalj imagingbiomarkersofalzheimerdiseaseinmultiplesclerosis
AT reichardrossr imagingbiomarkersofalzheimerdiseaseinmultiplesclerosis
AT przybelskiscotta imagingbiomarkersofalzheimerdiseaseinmultiplesclerosis
AT lesnicktimothyg imagingbiomarkersofalzheimerdiseaseinmultiplesclerosis
AT schwarzchristopherg imagingbiomarkersofalzheimerdiseaseinmultiplesclerosis
AT senjemmatthewl imagingbiomarkersofalzheimerdiseaseinmultiplesclerosis
AT gunterjeffreyl imagingbiomarkersofalzheimerdiseaseinmultiplesclerosis
AT parisijosephe imagingbiomarkersofalzheimerdiseaseinmultiplesclerosis
AT machuldamarym imagingbiomarkersofalzheimerdiseaseinmultiplesclerosis
AT vemuriprashanthi imagingbiomarkersofalzheimerdiseaseinmultiplesclerosis
AT mielkemichellem imagingbiomarkersofalzheimerdiseaseinmultiplesclerosis
AT knopmandavids imagingbiomarkersofalzheimerdiseaseinmultiplesclerosis
AT petersenronaldc imagingbiomarkersofalzheimerdiseaseinmultiplesclerosis
AT jackcliffordr imagingbiomarkersofalzheimerdiseaseinmultiplesclerosis
AT kantarciorhunh imagingbiomarkersofalzheimerdiseaseinmultiplesclerosis
AT kantarcikejal imagingbiomarkersofalzheimerdiseaseinmultiplesclerosis